Compounds > imatinib mesylate
Page last updated: 2024-09-03

imatinib mesylate and Syndrome

imatinib mesylate has been researched along with Syndrome in 4 studies

Research

Studies (4)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's2 (50.00)29.6817
2010's1 (25.00)24.3611
2020's1 (25.00)2.80

Authors

AuthorsStudies
Bjerkeseth, PO; Bredrup, C; Pfeiffer, HCV; Prescott, TE; Rustad, CF; Tveten, K1
Arts, FA; Chand, D; Constantinescu, S; Demoulin, JB; Hallberg, B; Pecquet, C; Velghe, AI1
de Lange, J; van den Akker, HP; van den Berg, H; van Rijn, RR1
Battistella, M; Dubertret, L; Frémont, G; Gornet, JM; Vignon-Pennamen, MD; Viguier, M1

Other Studies

4 other study(ies) available for imatinib mesylate and Syndrome

ArticleYear
Positive response to imatinib in PDGFRB-related Kosaki overgrowth syndrome.
    American journal of medical genetics. Part A, 2021, Volume: 185, Issue:8

    Topics: Child; Disease Management; Genetic Association Studies; Genetic Predisposition to Disease; Genetic Variation; Humans; Imatinib Mesylate; Male; Phenotype; Receptor, Platelet-Derived Growth Factor beta; Syndrome; Treatment Outcome

2021
PDGFRB mutants found in patients with familial infantile myofibromatosis or overgrowth syndrome are oncogenic and sensitive to imatinib.
    Oncogene, 2016, 06-23, Volume: 35, Issue:25

    Topics: Animals; Blotting, Western; Cell Line; Cell Line, Tumor; Cell Proliferation; Cell Transformation, Neoplastic; Female; Growth Disorders; Humans; Imatinib Mesylate; MCF-7 Cells; Mice; Mice, Inbred BALB C; Mice, Knockout; Mutagenesis, Site-Directed; Mutation; Myofibromatosis; Neoplasms, Experimental; NIH 3T3 Cells; Oncogenes; Protein Kinase Inhibitors; Receptor, Platelet-Derived Growth Factor beta; Syndrome

2016
Regression of central giant cell granuloma by a combination of imatinib and interferon: a case report.
    The British journal of oral & maxillofacial surgery, 2009, Volume: 47, Issue:1

    Topics: Adolescent; Antineoplastic Agents; Benzamides; Calcitonin; Collagen Diseases; Drug Combinations; Female; Granuloma, Giant Cell; Humans; Imatinib Mesylate; Interferon alpha-2; Interferon-alpha; Mandibular Diseases; Piperazines; Polyethylene Glycols; Pyrimidines; Recombinant Proteins; Remission Induction; Syndrome

2009
Imatinib-induced hand-foot syndrome in a patient with metastatic gastrointestinal stromal tumor.
    Archives of dermatology, 2008, Volume: 144, Issue:10

    Topics: Benzamides; Biopsy, Needle; Drug Eruptions; Erythema; Follow-Up Studies; Foot Dermatoses; Gastrointestinal Stromal Tumors; Hand Dermatoses; Humans; Imatinib Mesylate; Immunohistochemistry; Liver Neoplasms; Male; Middle Aged; Neoplasm Staging; Piperazines; Protein Kinase Inhibitors; Pyloric Antrum; Pyrimidines; Risk Assessment; Stomach Neoplasms; Syndrome

2008